COSMOS Pharmaceutical Corporation
株式会社コスモス薬品
Valuation
Fundamental ratios for the latest reported period.
Ticker: 3349
FY2025 (May 2026) · J-GAAP · consolidated Source: filing S100YYDI
FY = fiscal year, named by the calendar year it starts in; the month in brackets is when it ends (FY2025 ends Mar 2026 for a March year-end). FY2025 (May 2026) runs Jun 1, 2025 – May 31, 2026.
| Gross margin | 20.9% |
|---|---|
| Operating margin | 3.9% |
| Net margin | 2.9% |
| Return on equity | 11.8%Includes one-off items (e.g. gains on negative goodwill) |
| Return on assets | 5.7% |
| Revenue growth (YoY) | 8.7% |
| EPS (basic) | ¥404.33 |
| EPS growth (YoY) | 3.4% |
| Current ratio | 0.77x |
| Equity ratio | 47.6% |
| Book value / share | ¥3,579.49 |
| Free cash flow | −¥11.7B |